Hematopoietic stem cell transplantation (HSCT) is a treatment modality that allows the administration of high intensity chemotherapy (conditioning) without causing a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets or when the infusion of hematopoietic stem cells (both autologous or allogeneic) are taken place. Since hematopoietic progenitor cells may be obtained either from bone marrow (BM), peripheral blood (PB) or umbilical cord blood (UCB), different sources of cells may be selected.
Peripheral cells collected by apheresis machine after developing from the bone marrow to PB. The technique of apheresis is usually applied in more than 90% of autologous bone marrow transplants (BMT) and in approximately 70% of allogeneic BMT.
The advantages of PBSCs over BM stem cells in autologous settings include faster hematopoietic recovery, better immunological reconstitution and a relatively easy collection process.
Peripheral cells collected by apheresis machine after developing from the bone marrow to PB. The technique of apheresis is usually applied in more than 90% of autologous bone marrow transplants (BMT) and in approximately 70% of allogeneic BMT.
The advantages of PBSCs over BM stem cells in autologous settings include faster hematopoietic recovery, better immunological reconstitution and a relatively easy collection process.